WO2019090244A2 - Analyse in vitro de grappe de cellules suppressives dérivées de myéloïdes - Google Patents

Analyse in vitro de grappe de cellules suppressives dérivées de myéloïdes Download PDF

Info

Publication number
WO2019090244A2
WO2019090244A2 PCT/US2018/059242 US2018059242W WO2019090244A2 WO 2019090244 A2 WO2019090244 A2 WO 2019090244A2 US 2018059242 W US2018059242 W US 2018059242W WO 2019090244 A2 WO2019090244 A2 WO 2019090244A2
Authority
WO
WIPO (PCT)
Prior art keywords
mdsc
cells
selectin
mice
blood
Prior art date
Application number
PCT/US2018/059242
Other languages
English (en)
Other versions
WO2019090244A3 (fr
Inventor
Sharon Evans
Scott Abrams
Max Wicha
Original Assignee
Health Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research, Inc. filed Critical Health Research, Inc.
Publication of WO2019090244A2 publication Critical patent/WO2019090244A2/fr
Publication of WO2019090244A3 publication Critical patent/WO2019090244A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé d'identification de l'état immunosuppresseur d'un individu comprenant la détection de la formation d'une formation de groupe de cellules suppressives dérivées de myéloïdes circulantes (MDSC) dans un échantillon de sang obtenu à partir d'un individu. La formation de groupe MDSC peut être identifiée dans des frottis sanguins frais ou dans des échantillons de sang par cytométrie de flux.
PCT/US2018/059242 2017-11-03 2018-11-05 Analyse in vitro de grappe de cellules suppressives dérivées de myéloïdes WO2019090244A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581438P 2017-11-03 2017-11-03
US62/581,438 2017-11-03

Publications (2)

Publication Number Publication Date
WO2019090244A2 true WO2019090244A2 (fr) 2019-05-09
WO2019090244A3 WO2019090244A3 (fr) 2019-06-13

Family

ID=66331490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/059242 WO2019090244A2 (fr) 2017-11-03 2018-11-05 Analyse in vitro de grappe de cellules suppressives dérivées de myéloïdes

Country Status (1)

Country Link
WO (1) WO2019090244A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021092190A1 (fr) * 2019-11-05 2021-05-14 Health Research, Inc. Polythérapie contre le cancer
WO2022132041A1 (fr) * 2020-12-15 2022-06-23 Agency For Science, Technology And Research Procédé destiné à caractériser un neutrophile immunosuppressif
CN114739890A (zh) * 2022-04-15 2022-07-12 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 人MDSCs在鉴别CAA和AAA中的应用及鉴别试剂盒

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013312211B2 (en) * 2012-09-07 2018-03-29 King's College London VISTA modulators for diagnosis and treatment of cancer
WO2015189395A1 (fr) * 2014-06-13 2015-12-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pour le diagnostic, la surveillance et le traitement du cancer
US9777061B2 (en) * 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021092190A1 (fr) * 2019-11-05 2021-05-14 Health Research, Inc. Polythérapie contre le cancer
WO2022132041A1 (fr) * 2020-12-15 2022-06-23 Agency For Science, Technology And Research Procédé destiné à caractériser un neutrophile immunosuppressif
CN114739890A (zh) * 2022-04-15 2022-07-12 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 人MDSCs在鉴别CAA和AAA中的应用及鉴别试剂盒
CN114739890B (zh) * 2022-04-15 2022-12-13 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 人MDSCs在鉴别CAA和AAA中的应用及鉴别试剂盒

Also Published As

Publication number Publication date
WO2019090244A3 (fr) 2019-06-13

Similar Documents

Publication Publication Date Title
Asrir et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy
Anzai et al. The infarcted myocardium solicits GM-CSF for the detrimental oversupply of inflammatory leukocytes
Georgoudaki et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis
Rieger et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD
JP6557827B2 (ja) 癌治療用医薬組成物
Khanna et al. Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti–PD-L1 antibody avelumab
Campbell et al. Fc-optimized anti-CCR8 antibody depletes regulatory T cells in human tumor models
Chen et al. Immune dysregulation in patients with PTEN hamartoma tumor syndrome: analysis of FOXP3 regulatory T cells
Chen et al. Induction of myelodysplasia by myeloid-derived suppressor cells
Fiedler et al. Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia
Solis-Castillo et al. Tumor-infiltrating regulatory T cells, CD8/Treg ratio, and cancer stem cells are correlated with lymph node metastasis in patients with early breast cancer
Rossi et al. Mouse models of multiple myeloma: technologic platforms and perspectives
AU2016270996A1 (en) Methods to induce conversion of regulatory T cells into effector T cells for cancer immunotherapy
US20170198039A1 (en) Methods for treating cancer
WO2019090244A2 (fr) Analyse in vitro de grappe de cellules suppressives dérivées de myéloïdes
JP2018515069A (ja) Ｔｎｆｒｓｆ１４／ｈｖｅｍタンパク質およびその使用の方法
Leiva et al. Haematopoietic ESL-1 enables stem cell proliferation in the bone marrow by limiting TGFβ availability
Tecchio et al. Uncovering the multifaceted roles played by neutrophils in allogeneic hematopoietic stem cell transplantation
Jing et al. T cells deficient in diacylglycerol kinase ζ are resistant to PD-1 inhibition and help create persistent host immunity to leukemia
Du et al. Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation
Haake et al. Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment
WO2016081889A1 (fr) Inhibiteur recombinant de la c1-estérase et utilisation de celui-ci
Kumar et al. Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8+ T cells
JP6912800B2 (ja) 造血器腫瘍治療剤、およびスクリーニング方法
Shan et al. How to establish acute myeloid leukemia xenograft models using immunodeficient mice

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18872951

Country of ref document: EP

Kind code of ref document: A2